Alcoholic liver will lead cirrhosis management sales through 2036 with a 52.0% share in 2026 as the leading disease indication segment. The market is expected to reach USD 878.3 million in 2026 and USD 1664.2 million by 2036, creating an absolute opportunity of USD 785.9 million between 2026 and 2036.